人类肺癌和胰腺癌中p21/WAF1基因无突变。
Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers.
作者信息
Shimizu T, Miwa W, Nakamori S, Ishikawa O, Konishi Y, Sekiya T
机构信息
Oncogene Division, National Cancer Center Research Institute, Tokyo.
出版信息
Jpn J Cancer Res. 1996 Mar;87(3):275-8. doi: 10.1111/j.1349-7006.1996.tb00217.x.
Abstract
The expression of a negative regulator of the cell cycle, p21WAF1 protein, is trans-activated by wild-type p53, but not by the mutant protein. Therefore, mutations of the p53 and WAF1 genes may be complementary. We examined DNAs from 70 human primary lung (63 of NSCLC and 7 of SCLC) and 24 pancreatic cancers (19 primary cancers and 5 cell lines) for mutations of the WAF1 gene. No mutations were detected in any samples examined, regardless of the mutational state of the p53 gene. The results suggested that aberrations of the coding sequence of the WAF1 gene are not associated with carcinogenesis in lung and pancreatic cancers.
摘要
细胞周期负调控因子p21WAF1蛋白的表达可被野生型p53反式激活，而不能被突变蛋白激活。因此，p53和WAF1基因的突变可能具有互补性。我们检测了70例人原发性肺癌（63例非小细胞肺癌和7例小细胞肺癌）和24例胰腺癌（19例原发性癌和5个细胞系）的DNA中WAF1基因的突变情况。在所检测的任何样本中均未检测到突变，无论p53基因的突变状态如何。结果表明，WAF1基因编码序列的畸变与肺癌和胰腺癌的发生无关。
相似文献
1
Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers.人类肺癌和胰腺癌中p21/WAF1基因无突变。
Jpn J Cancer Res. 1996 Mar;87(3):275-8. doi: 10.1111/j.1349-7006.1996.tb00217.x.
2
3
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).使用低体积活检组织的全基因组扩增（WGA）来评估表皮生长因子受体（EGFR）、 Kirsten 大鼠肉瘤病毒癌基因（KRAS）、p53和间质上皮转化因子（CMET）突变在晚期非小细胞肺癌（NSCLC）中的预后作用。
J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.
4
Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.非小细胞肺癌（NSCLC）肿瘤及手术切缘中p53和k-ras密码子12突变的低频率
Tumori. 2007 Sep-Oct;93(5):473-7. doi: 10.1177/030089160709300511.
5
Association between p53 mutation and clinicopathological features of non-small cell lung cancer.p53突变与非小细胞肺癌临床病理特征之间的关联。
Jpn J Clin Oncol. 1997 Aug;27(4):211-5. doi: 10.1093/jjco/27.4.211.
6
Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations.在缺乏p53突变的乳腺癌中，WAF1基因改变在异常细胞周期调控中不起作用。
Clin Cancer Res. 1997 Sep;3(9):1669-73.
7
Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.人类肺癌中新型候选肿瘤抑制基因ING1和ING2的改变。
Oncol Rep. 2006 Mar;15(3):545-9.
8
Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan.台湾地区p21WAF1/CIP1基因多态性与肺癌易感性及预后相关性的证据缺失。
Jpn J Cancer Res. 2000 Jan;91(1):9-15. doi: 10.1111/j.1349-7006.2000.tb00854.x.
9
ERBB2 kinase domain mutation in the lung squamous cell carcinoma.肺鳞状细胞癌中的ERBB2激酶结构域突变
Cancer Lett. 2006 Jun 8;237(1):89-94. doi: 10.1016/j.canlet.2005.05.026. Epub 2005 Jul 18.
10
p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung.p21表达作为肺鳞状细胞癌预后良好的预测指标。
Clin Cancer Res. 1997 Oct;3(10):1831-5.
引用本文的文献
1
Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.Cip/Kip细胞周期抑制剂：神经肿瘤学视角
J Neurooncol. 2001 Feb;51(3):205-18. doi: 10.1023/a:1010671908204.
2
Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan.台湾地区p21WAF1/CIP1基因多态性与肺癌易感性及预后相关性的证据缺失。
Jpn J Cancer Res. 2000 Jan;91(1):9-15. doi: 10.1111/j.1349-7006.2000.tb00854.x.
3
p21WAF1/CIP1 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression.p21WAF1/CIP1在妊娠滋养细胞疾病中的表达：与临床病理参数、Ki67及p53基因表达的相关性
J Clin Pathol. 1998 Feb;51(2):159-62. doi: 10.1136/jcp.51.2.159.
4
Molecular diagnosis of pancreas carcinoma.胰腺癌的分子诊断
J Clin Lab Anal. 1997;11(4):225-31. doi: 10.1002/(sici)1098-2825(1997)11:4<225::aid-jcla9>3.0.co;2-7.
5
Failure to detect mutations in the retinoblastoma protein-binding domain of the transcription factor E2F-1 in human cancers.在人类癌症中未能检测到转录因子E2F-1的视网膜母细胞瘤蛋白结合结构域中的突变。
Jpn J Cancer Res. 1996 Dec;87(12):1204-9. doi: 10.1111/j.1349-7006.1996.tb03134.x.
本文引用的文献
1
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.细胞周期调控中的一种新调控基序，可特异性抑制细胞周期蛋白D/细胞周期蛋白依赖性激酶4。
Nature. 1993 Dec 16;366(6456):704-7. doi: 10.1038/366704a0.
2
WAF1, a potential mediator of p53 tumor suppression.WAF1，一种p53肿瘤抑制的潜在介导因子。
Cell. 1993 Nov 19;75(4):817-25. doi: 10.1016/0092-8674(93)90500-p.
3
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.p21 Cdk相互作用蛋白Cip1是G1期细胞周期蛋白依赖性激酶的有效抑制剂。
Cell. 1993 Nov 19;75(4):805-16. doi: 10.1016/0092-8674(93)90499-g.
4
5
Induction of WAF1/CIP1 by a p53-independent pathway.通过一条不依赖p53的途径诱导WAF1/CIP1。
Cancer Res. 1994 Jul 1;54(13):3391-5.
6
7
G1 phase progression: cycling on cue.G1期进程：依信号循环
Cell. 1994 Nov 18;79(4):551-5. doi: 10.1016/0092-8674(94)90540-1.
8
Absence of WAF1 mutations in a variety of human malignancies.
Blood. 1994 Dec 1;84(11):3781-4.
9
The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.细胞周期蛋白依赖性激酶的p21抑制剂通过与增殖细胞核抗原相互作用来控制DNA复制。
Nature. 1994 Jun 16;369(6481):574-8. doi: 10.1038/369574a0.
10
Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer.结直肠癌中WAF1-CIP1基因的多态性及可能不存在的突变
Oncogene. 1995 Feb 2;10(3):599-601.
Zotero 插件